Abstract 491: Melanoma patients with multi-Siglec ligands as profiled by HYDRA technology are refractory to PD1 blockade

Authors: Adam Petrone, Dennie T. Frederick, Jillian M. Prendergast, James Broderick, Karl Normington, Genevieve Boland, Li Peng

Published: 2021-07-01

DOI: 10.1158/1538-7445.am2021-491

Source: Full article